Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, which covers methods of using LP-284 to treat mantle cell lymphoma, double-hit lymphoma, and other blood cancers. The allowed claims include LP-284 as a monotherapy and in combination with several classes of anti-cancer agents.
Once issued, the patent is expected to extend LP-284 intellectual property protection into 2042, adding method-of-use protection to Lantern’s existing composition-of-matter patent estate. This development is significant because it strengthens the company’s competitive position in the oncology space and could provide a longer period of market exclusivity for LP-284, a drug developed through Lantern’s RADR artificial intelligence platform.
LP-284 is currently being evaluated in an ongoing Phase 1a dose-escalation clinical trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma and solid tumors. The drug has received three FDA Orphan Drug Designations, including for MCL, high-grade B-cell lymphoma with MYC and BCL2 rearrangements, and soft tissue sarcomas. These designations underscore the unmet medical need in these hard-to-treat cancers and highlight LP-284’s potential to address them.
The patent allowance is important for Lantern Pharma because it provides broader intellectual property coverage that can protect the company’s investment in LP-284 and potentially enhance its value for licensing or partnership opportunities. For investors, this news demonstrates progress in building a robust patent portfolio around the company’s AI-discovered pipeline, which also includes LP-184 and LP-300, as well as a central-nervous-system-focused subsidiary, Starlight Therapeutics, and an AI subsidiary, Open-Medicine AI.
For those following the company, the latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN. To view the full press release, visit https://ibn.fm/5zEya.
MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community, distributed the announcement. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries; article and editorial syndication to 5,000+ outlets; enhanced press release enhancement to ensure maximum impact; social media distribution via IBN to millions of social media followers; and a full array of tailored corporate communications solutions.
For more information about MissionIR, please visit MissionIR.
